ERBB2 and breast carcinoma: Several studies have correlated the overexpression of the HER2/neu oncogene with poor prognosis in breast cancer patients [10,11], and demonstrated that evaluating HER2/neu protein by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and chromogenic in situ hybridization (CISH) are important in selecting optimal therapy and predicting prognosis in breast cancer patients [12-14].